PSMA Radioligand Therapy | Advances in Prostate Cancer Treatments | Part 4
Published Date: March 24, 2022
Theranostics includes a molecular imaging guided approach to determine the tumor target and exactly which patients are appropriate for PSMA Radioligand Therapy and which patients are responding. PSMA PET aids in creating an individualized approach to treatment options for Prostate Cancer patients by answering the question; is this treatment effective in this patient? Nat Lenzo, MD explains.
Supported by Telix Pharmaceuticals as a service to medicine - Telix respects the independence of healthcare professionals and the views are those of the presenter.